MiR-448-5p/VEGFA Axis Protects Cardiomyocytes from Hypoxia Through Regulating the FAS/FAS-L Signaling Pathway

Hanqing Tang1, Shitian Zhang1, Cenhan Huang1

  • 1School of Basic Medicine, Youjiang Medical University for Nationalities.

Insights

MicroRNA-448-5p protects heart cells from hypoxia by targeting VEGFA and inhibiting the FAS/FAS-L pathway, reducing apoptosis and improving cell viability in myocardial infarction models.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Biochemistry

Background:

  • Myocardial infarction involves significant myocardial cell apoptosis.
  • MicroRNA-448-5p (miR-448-5p) expression increases in myocardial infarction, suggesting a role in apoptosis.
  • The protective role of miR-448-5p in hypoxic cardiomyocytes requires elucidation.

Purpose of the Study:

  • To investigate the protective effects of miR-448-5p on cardiomyocytes under hypoxic conditions.
  • To explore the molecular mechanisms underlying miR-448-5p's action, including its targets and signaling pathways.

Main Methods:

  • Establishment of a hypoxia model using H9C2 cells subjected to anoxia.
  • Transfection with miR-448-5p mimic and inhibitor to modulate its expression.
  • Dual-luciferase assay to confirm miR-448-5p targeting of VEGFA.
  • Assessment of cell viability (CCK-8 assay) and apoptosis (flow cytometry).
  • Measurement of apoptosis-related proteins (Bcl-2, Bax, cleaved caspase-3) and FAS/FAS-L via Western blotting and qRT-PCR.

Main Results:

  • Hypoxia reduced H9C2 cell viability and increased apoptosis.
  • miR-448-5p mimic counteracted hypoxia-induced apoptosis and cell death, while the inhibitor exacerbated these effects.
  • miR-448-5p directly targeted VEGFA, and its mimic inhibited hypoxia-induced increases in FAS and FAS-L expression.

Conclusions:

  • The miR-448-5p/VEGFA axis plays a crucial protective role in cardiomyocytes against hypoxia.
  • This protection is mediated by the inhibition of the FAS/FAS-L signaling pathway.
  • miR-448-5p represents a potential therapeutic target for myocardial infarction.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.8K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
114
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.2K